BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:With a flurry of high capital collaborations and partnership d eals from the likes of C4T\, Merck US and KgGA\, Monte Rosa\, Proxygen\, Orum\, and momentum building in clinic with BTK degraders\, ER degraders and many more assets\, it has never been more import to re-join forces at the 7th TPD and Induced Proximity Summit\, the longest standing and most comprehensive protein degradation and proximity based conference\, retur ning to Downtown Boston\, October 28 - 31\, 2024.\n\nSpanning foundationa l research and discovery\, through to IND-filing and clinical trials\, th is is the world's definitive meeting to discuss opportunities and challen ges the TPD and Induced Proximity field must address to expand the target space and facilitate the discovery and development of therapeutically re levant degraders\, blockers\, stabilizers and inducers of protein-protein interactions. Whether you're entering the TPD and Induced Proximity spac e for the first time or a well-seasoned TPD veteran\, this forum will equ ip you with the knowhow and connections to make rapid advances in your wo rk.\n\nAssembling over 550 TPD and Induced Proximity enthusiasts from acr oss every corner of the landscape\, we have left no stone unturned in our duty to continue to deliver the full breadth and depth of protein degrad ation and modulation research with SureTACs\, EpiTACs\, RIPTACs\, Molecul ar Gates\, and so much more.\n\nThe 7th TPD and Induced Proximity Summit is the field's singular\, one-stop-shop to gain unparalleled overview of cutting-edge R and D\, whilst diving deep into end-to-end development str ategy to propel degraders towards the first clinical approval.\n\nURLs:Ti ckets: \;https://go.evvnt.com/2481570-2?pid=185Brochure: \;https: //go.evvnt.com/2481570-3?pid=185\n\nPrices:Drug Developer Pricing - (4 Da y Pass) Industry Days + New Frontiers Day + Next Generation Day: USD 6295 .00\,Drug Developer Pricing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Generation Day: USD 4797.00\,Drug Developer Pricing - (2 Day Pass) Industry Days Only: USD 3299.00\,Academic Pricing - (4 Day Pass) In dustry Days + New Frontiers Day + Next Generation Day: USD 5495.00\,Acade mic Pricing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Gene ration Day: USD 4197.00\,Academic Pricing - (2 Day Pass) Industry Days On ly: USD 2899.00\,Service Provider Pricing - (4 Day Pass) Industry Days + New Frontiers Day + Next Generation Day: USD 7295.00\,Service Provider Pr icing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Generation Day: USD 5597.00\,Service Provider Pricing - (2 Day Pass) Industry Days Only: USD 3899.00\n\nSpeakers: \;Abhishek Dogra\, Director\, Medicina l Chemistry and Induced Proximity\, A-Alpha Bio\, Adrian Gottschalk\, Pre sident and Chief Executive Officer\, Foghorn Therapeutics\, Alessio Ciull i\, Director of the Centre for Targeted Protein Degradation\, University of Dundee\, Amine Sadok\, Director\, Induced Proximity Platform\, Amgen\, Andreas Reichel\, Vice President\, Head Of DMPK Modelling and Simulation s\, Bayer\, Andrew Tsourkas\, Professor\, University of Pennsylvania\, An ita C. Bellail\, Chief Scientific Officer and Co-Founder\, HB Therapeutic s\, Ankit Sharma\, Associate Director\, Medicinal Chemistry\, Oncology Ta rgeted Discovery\, AstraZeneca\, Arnout Schepers\, Founder and Chief Exec utive Officer\, TenAces Biosciences\, Arthur Sands\, President and Chief Executive Officer\, Nurix Therapeutics\, Arvind Shakya\, Director\, BioTh eryx\, Barbara Lueckel\, Global Head\, Research Technologies Partnering\, Pharma Partnering\, F. Hoffmann-La Roche\, Benedict Cross\, CTO\, Phorem ost\, Bernd Boidol\, Chief Executive Officer\, Proxygen\, Bradlee Heckman n\, Chief Scientific Officer\, Asha Therapeutics\, Carolyn Porter\, Chief Executive Officer\, Outrun Therapeutics\, Charu Chaudhry\, Senior Princi pal Scientist\, Novartis\, Chinatsu Sakata-Sakur\, Vice President\, Astel las Pharma\, Christian Dillon\, Chief Scientific Officer\, PhoreMost\, Ch ristian Ottmann\, Associate Professor\, Eindhoven University of Technolog y\, Christina Woo\, Associate Professor\, Harvard University\, Dan Finley \, Professor\, Harvard Medical School\, Diogo Feleciano\, Co-Founder and Chief Operating Officer\, Booster Therapeutics\, Dmitri Ivanov\, Associat e Professor\, UT Health San Antonio\, Effie Tozzo\, Chief Scientific Offi cer\, Avilar Therapeutics\, Elena De Vita\, Assistant Professor\, Queen M ary University of London\, Elizabeth Caine\, Scientist\, Promega\, Eric F ischer\, Professor and Director Chemical Biology Program Harvard Medical School - Director - DFCI\, Center for Protein Degradation\, Eugene Chekle r\, Director\, Bristol Myers Squibb\, Gang Yao\, Associate Director Encod ed Oncology\, GSK\, Gary Kleiger\, Chair and Professor\, University of La s Vegas\, Nevada\, Giovanni Spagnolli\, Co-Founder and Chief Technology O fficer\, Sibylla Biotech\, Gisele Nishiguchi\, Group Leader\, St. Jude Ch ildren's Research Hospital\, Greg Michaud\, Director\, Novartis AG\, Hail ong Zhang\, Chief Executive Officer\, Blueray Biopharma\, Henrik Daub\, F ounder and Chief Scientific Officer\, NEOsphere Biotechnologies\, Ian Chu rcher\, Consultant\, Janus Drug Discovery\, Jaehyun Choi\, Chief Executiv e Officer\, EPD Biotherapeutics\, James Papatzimas\, Principal Scientist\ , Novartis\, Jason Kantor\, Chief Business Officer\, Nurix Therapeutics\, Jessica Sims\, Principal Scientist Toxicology\, Genentech\, JF Brazeau\, Director\, Plexium\, Jian Jin\, Mount Sinai Endowed Professor\, Icahn Sc hool of Medicine at Mount Sinai\, Joachim Rudolph\, Senior Fellow Discove ry Chemistry\, Genentech\, Johan Johansson\, Associate Principal Scientis t\, CVRM PROTAC Lead\, Project Leader\, AstraZeneca\, John Houston\, Chai rperson\, Chief Executive Officer\, and President\, Arvinas\, Juliet Will iams\, Head of Research\, Kymera Therapeutics\, Kanak Raina\, Senior Dire ctor Biology\, Halda Therapeutics\, Karteek Kadimisetty\, Director\, Life Sensors\, Ken Yamada\, Associate Director\, Novartis\, Keunsoo Kang\, Chi ef Scientific Officer\, Deargen\, Kylie Walters\, Senior Investigator and Section Chief\, National Institutes of Health\, Len Reyno\, Chief Medica l Officer\, C4 Therapeutics\, Leo Fu\, Co-Founder and Chief Technology Of ficer\, GluBio Therapeutics\, Lise Loberg\, Preclinical Safety Expert\, A bbVie\, Magnus Walter\, Senior Vice President Drug Discovery\, Monte Rosa Therapeutics\, Mark Niosi\, Principal Scientist\, Pfizer\, Matthias Bran d\, Co-Founder and Chief Scientific Officer\, Proxygen\, Maureen Spit\, V ice President Research\, Laigo Bio\, Nadeem Vellore\, Principal Scientist \, Johnson and Johnson\, Nan Ji\, Co-Founder\, President and Chief Execut ive Officer\, PAQ Therapeutics\, Natalie Nairn\, Co-Founder\, Chief Execu tive Officer and Chief Scientific Officer\, Cyclera Therapeutics\, Neil B ence\, Site Head and Vice President\, Bristol Myers Squibb\, Nello Mainol fi\, Chief Executive Officer\, Kymera Therapeutics\, Pat Sharp\, Senior V ice President Discovery Sciences\, Gate Bioscience\, Paula O'Connor\, Chi ef Medical Officer\, Nurix Therapeutics\, Peggy Scherle\, Chief Scientifi c Officer\, Prelude Therapeutics\, Radoslav Enchev\, Group Leader\, The F rancis Crick Institute\, Raegan O'Lone\, Senior Program Advisor\, HESI\, Randolph Lopez\, Co-Founder and Chief Technology Officer\, A-Alpha Bio\, Randy Teel\, Chief Business Officer\, Arvinas\, Riccardo Sabatini\, Chief Data Scientist\, Orionis Biosciences\, Rick Ewing\, Vice President Head of Chemistry\, Rapafusyn\, Ryan Kerrigan\, Principal Scientist\, Novartis \, Scott Boyle\, Chief Business Officer\, C4 Therapeutics\, Sharon Townso n\, Chief Technology Officer\, Monte Rosa Therapeutics\, Shyra Gardai\, C hief Scientific Officer\, EpiBiologics\, Stephanie Leuenroth-Quinn\, Phar macologist\, FDA\, Steven Banik\, Assistant Professor\, Stanford Universi ty\, Steven Bellon\, Chief Scientific Officer\, Foghorn Therapeutics\, St ewart Fisher\, Chief Scientific Officer\, C4 Therapeutics\, Stuart Schrei ber\, Founding Chief Executive Officer\, Arena Bioworks\, William Housley \, Principal Research Scientist\, Abbvie\, Wu Du\, Senior Vice President Medicinal Chemistry\, Hinova Pharmaceuticals\, Xiaoran Han\, Vice Preside nt\, Discovery Medicine\, Cullgen\, Ya-Wen\, Lu Associate Director\, Nuri x Therapeutics\, Yao Wang\, Chief Medical Officer\, Kangpu Biopharmaceuti cals\, Yong Cang\, Co-Founder and Chief Scientific Officer\, Degron Thera peutics\, Zoran Rankovic\, Director\, Centre for Protein Degradation\, Th e Institute for Cancer Research\n\nCategory: \;Conferences | Science\ , Health and Medicine\n\nDate and Time: \;28th October 2024 at 9:00 a m to 31st October 2024 at 5:00 pm\n DTEND:20241031T170000 DTSTAMP:20260512T214300Z DTSTART:20241028T090000 LOCATION:The Westin Copley Place\, Boston\, 10\, Huntington Avenue\, Bosto n\, Massachusetts\, 02116\, SEQUENCE:0 SUMMARY:With a flurry of high capital collaborations and partnership deals from the likes of C4T\, Merck US and KgGA\, Monte Rosa\, Proxygen\, Orum \, and moment... UID:4efb15d2-8962-4fbd-bb79-32a7f89124e7 END:VEVENT END:VCALENDAR